Clinical Trials
9 trialsNCT06947291 2025-09-08
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Recruiting
NCT06829459 2025-04-08
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Shanghai JMT-Bio Inc.
Phase 3 Recruiting
NCT06908772 2025-04-03
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Shanghai JMT-Bio Inc.
Phase 2/3 Not yet recruiting
NCT03457532 2024-11-01
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Haihe Biopharma Co., Ltd.
Phase 1 Completed
NCT03466268 2024-10-09
Study to Evaluate the Safety and Anti-tumor Activity of SCC244
Haihe Biopharma Co., Ltd.
Phase 1 Completed
NCT06525350 2024-07-29
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT06452433 2024-06-11
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04270591 2022-08-01
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Haihe Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT04338243 2020-04-08
Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
Haihe Biopharma Co., Ltd.
Phase 1/2 Unknown